Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Oza AM, et al. Among authors: provencher d. Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4. Gynecol Oncol. 2017. PMID: 28882436 Free article. Clinical Trial.
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J, Lubinski J, Lynch HT, Klijn J, Ghadirian P, Neuhausen SL, Kim-Sing C, Foulkes WD, Moller P, Isaacs C, Domchek S, Randall S, Offit K, Tung N, Ainsworth P, Gershoni-Baruch R, Eisen A, Daly M, Karlan B, Saal HM, Couch F, Pasini B, Wagner T, Friedman E, Rennert G, Eng C, Weitzel J, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group; Garber J, Osborne M, Fishman D, McLennan J, McKinnon W, Merajver S, Olsson H, Provencher D, Pasche B, Evans G, Meschino WS, Lemire E, Chudley A, Rayson D, Bellati C. Kotsopoulos J, et al. Among authors: provencher d. Breast Cancer Res Treat. 2007 Oct;105(2):221-8. doi: 10.1007/s10549-006-9441-3. Epub 2007 Jan 24. Breast Cancer Res Treat. 2007. PMID: 17245541
Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.
Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A; IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada. Fung-Kee-Fung M, et al. Among authors: provencher d. Gynecol Oncol. 2007 Jun;105(3):747-56. doi: 10.1016/j.ygyno.2007.02.015. Epub 2007 Mar 21. Gynecol Oncol. 2007. PMID: 17368522
Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.
Oza AM, Eisenhauer EA, Elit L, Cutz JC, Sakurada A, Tsao MS, Hoskins PJ, Biagi J, Ghatage P, Mazurka J, Provencher D, Dore N, Dancey J, Fyles A. Oza AM, et al. Among authors: provencher d. J Clin Oncol. 2008 Sep 10;26(26):4319-25. doi: 10.1200/JCO.2007.15.8808. Epub 2008 Jun 30. J Clin Oncol. 2008. PMID: 18591547 Clinical Trial.
Mutation of FOXL2 in granulosa-cell tumors of the ovary.
Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provencher D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao Y, Zeng T, Glover JN, Vanderhyden B, Zhao C, Parkinson CA, Jimenez-Linan M, Bowtell DD, Mes-Masson AM, Brenton JD, Aparicio SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG. Shah SP, et al. Among authors: provencher d. N Engl J Med. 2009 Jun 25;360(26):2719-29. doi: 10.1056/NEJMoa0902542. Epub 2009 Jun 10. N Engl J Med. 2009. PMID: 19516027 Free article.
283 results